Clinigen to manage chemotherapy overdose treatment programme for BTG
Clinigen’s (LON:CLIN) Global Access Programs (GAP) arm has extended its distribution agreement with BTG (LON:BTG) subsidiary Protherics Medicines to a third product. GAP will exclusively manage a named...
View ArticleClinigen seals epilepsy drug deal with Eisai
AIM-listed pharma company Clinigen (LON:CLIN) has unveiled a deal with Eisai that will see it manage an access programme for its anti-epilepsy drug Fycompa in Germany. The agreement will mean an...
View ArticleClinigen receives marketing authorisations for Cardioxane and VIBATIV
Specialty pharma group Clinigen (LON:CLIN) has achieved an important milestone towards adding two new products to its medicine cabinet. It has received European marketing authorisations for Cardioxane...
View ArticleClinigen revenues soar as all three operations grow
Global pharma and services business Clinigen (LON:CLIN) unveiled a 49% increase in group revenues for the year just ended driven by strong growth across all three of its operations. In the year to end...
View ArticleCity analysts hail Clinigen results
---ADDS BROKER COMMENT AND SHARE PRICE--- Global pharma and services business Clinigen (LON:CLIN) posted full year results on Wednesday that beat analysts' forecasts. The group unveiled a 49% increase...
View ArticleClinigen placing completes at 410p per share
Institutional investors have bought up just under 11% of the issued share capital of Clinigen (LON:CLIN) through a placing of shares at 410p each. The shares have been sold by directors and employees...
View ArticleClinigen extends distribution agreement with Accord
Clinigen Group (LON:CLIN) has extended its exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare to include capecitabine, an orally administered chemotherapeutic...
View ArticleUPDATE - Clinigen first half earnings rise 20%; investors given a dividend boost
--adds broker comment-- The speciality pharma and pharmaceutical services group Clinigen (LON:CLIN) revealed itself to be in rude financial health, posting a 20% rise in underlying first half earnings....
View Article
